Latest News and Press Releases
Want to stay updated on the latest news?
-
New York , Nov. 13, 2023 (GLOBE NEWSWIRE) -- The global blood culture test market size is slated to expand at 11.90% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 22...
-
YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
-
YONKERS, N.Y., Jan. 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
-
YONKERS, NY--(Marketwired - August 09, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
-
YONKERS, NY--(Marketwired - May 25, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
-
YONKERS, NY--(Marketwired - April 19, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
-
YONKERS, NY--(Marketwired - January 04, 2017) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
-
YONKERS, NY--(Marketwired - November 17, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
-
YONKERS, NY--(Marketwired - November 10, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
-
YONKERS, NY--(Marketwired - November 09, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...